Fructose-1,6-bisphosphatase 1 suppresses PPARα-mediated gene transcription and non-small-cell lung cancer progression

被引:0
|
作者
Shi, Rongkai [1 ,2 ]
Tao, Jingjing [1 ,2 ]
Jiang, Xiaoming [1 ,2 ]
Li, Min [1 ,2 ]
Zhu, Rongxuan [1 ,2 ]
Luo, Shudi [1 ,2 ]
Lu, Zhimin [1 ,2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Zhejiang Prov Key Lab Pancreat Dis,Inst Translat M, Hangzhou 310029, Zhejiang, Peoples R China
[2] Zhejiang Univ, Canc Ctr, Hangzhou 310029, Zhejiang, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 10期
基金
浙江省自然科学基金; 中国国家自然科学基金;
关键词
FBP1; non -small cell lung cancer (NSCLC); glutamine deprivation; phosphorylation; O-GlcNAcylation; prognostic biomarker; PROMOTES; PHOSPHORYLATION; EXPRESSION; KINASE; GROWTH; PGK1;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rapidly growing tumors often encounter energy stress, such as glutamine deficiency. However, how nor-mal and tumor cells differentially respond to glutamine deficiency remains largely unclear. Here, we demonstrate that glutamine deprivation activates PERK, which phosphorylates FBP1 at S170 and induces nuclear accumulation of FBP1. Nuclear FBP1 inhibits PPAR alpha-mediated beta-oxidation gene transcription in normal lung epithelial cells. In contrast, highly expressed OGT in non-small cell lung cancer (NSCLC) cells promotes FBP1 O-GlcNAcylation, which abrogates FBP1 phosphorylation and enhances beta-oxidation gene transcription to support cell proliferation under glutamine deficiency. In addition, FBP1 pS170 is negatively correlated with OGT expression in human NSCLC specimens, and low expression of FBP1 pS170 is associated with poor prognosis in NSCLC patients. These findings highlight the differential regulation of FBP1 in normal and NSCLC cells under glutamine deprivation and underscore the potential to target nuclear FBP1 for NSCLC treatment.
引用
收藏
页码:4742 / +
页数:15
相关论文
共 50 条
  • [31] Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer
    Rapp, Ulf R.
    Korn, Christian
    Ceteci, Fatih
    Karreman, Christiaan
    Luetkenhaus, Katharina
    Serafin, Valentina
    Zanucco, Emanuele
    Castro, Ines
    Potapenko, Tamara
    PLOS ONE, 2009, 4 (06):
  • [32] Gene expression profiling of non-small-cell lung cancer
    Lacroix, Ludovic
    Commo, Frederic
    Soria, Jean-Charles
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (02) : 167 - 178
  • [33] Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer
    Sheffield, B. S.
    Bosdet, I. E.
    Ali, R. H.
    Young, S. S.
    McNeil, B. K.
    Wong, C.
    Dastur, K.
    Karsan, A.
    Ionescu, D. N.
    CURRENT ONCOLOGY, 2014, 21 (06) : 305 - 308
  • [34] Transcription Factor p53 Suppresses Tumor Growth by Prompting Pyroptosis in Non-Small-Cell Lung Cancer
    Zhang, Tianze
    Li, Yongchao
    Zhu, Ruidong
    Song, Pengcheng
    Wei, Youlei
    Liang, Tian
    Xu, Guangquan
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2019, 2019
  • [35] CALCR knockdown inhibits the development and progression of non-small-cell lung cancer
    He, Tao
    Ling, Feng
    CARCINOGENESIS, 2021, 42 (11) : 1390 - 1398
  • [36] Identification of genes associated with non-small-cell lung cancer promotion and progression
    Bankovic, Jasna
    Stojsic, Jelena
    Jovanovic, Dragana
    Andjelkovic, Tijana
    Milinkovic, Vedrana
    Ruzdijic, Sabera
    Tanic, Nikola
    LUNG CANCER, 2010, 67 (02) : 151 - 159
  • [37] Fibronectin Promotes Tumor Angiogenesis and Progression of Non-small-Cell Lung Cancer
    Gao, G.
    Sun, J.
    Zhou, F.
    Ye, L.
    Li, W.
    Wu, F.
    Su, C.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S505 - S505
  • [38] Contributions of KRAS and RAL in Non-Small-Cell Lung Cancer Growth and Progression
    Guin, Sunny
    Ru, Yuanbin
    Wynes, Murry W.
    Mishra, Rangnath
    Lu, Xian
    Owens, Charles
    Baron, Anna E.
    Vasu, Vihas T.
    Hirsch, Fred R.
    Kern, Jeffrey A.
    Theodorescu, Dan
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1492 - 1501
  • [39] Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab
    Freeman, A. T.
    Lesperance, M.
    Wai, E. S.
    Croteau, N. S.
    Fiorino, L.
    Geller, G.
    Brooks, E. G.
    Poonja, Z.
    Fenton, D.
    Irons, S.
    Ksienski, D.
    CURRENT ONCOLOGY, 2020, 27 (02) : 76 - 82
  • [40] RAPID DISEASE PROGRESSION WITH DELAY IN TREATMENT OF NON-SMALL-CELL LUNG CANCER
    Mohammed, Nasiruddin
    Kestin, Larry Llyn
    Grills, Inga Siiner
    Battu, Madhu
    Fitch, Dwight Lamar
    Wong, Ching-yee Oliver
    Margolis, Jeffrey Harold
    Chmielewski, Gary William
    Welsh, Robert James
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (02): : 466 - 472